On profitability, management highlighted the introduction of adjusted, supplemental non-IFRS measures going forward, including adjusted EBITDA, to improve comparability. Klinger said adjustments in 2025 included a EUR 150 million non-cash impairment related to Swedencare and a EUR 148 million revaluation and reclassification of the Terpenes business (described as EBITDA-neutral), as well as smaller items tied to portfolio optimization, the ONE SYM Transformation program, and antitrust investigation-related ...